Thermo Fisher Scientific Introduces Decentralized Clinical Trials Network

New network supports rapid evolution and deployment of DCTs worldwide through DCT eLearning certification program

10/05/2022  WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced the creation of the PPD DCT Network to support global investigators and research sites participating in decentralized clinical trials (DCTs) for pharmaceutical and biotech customers. More>>

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

 How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials

How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials More>>

BRIM Biotechnology, Inc. Raises $20 Million in Series E Funding Round

Taipei, Taiwan, 1st December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding round. This demonstrates the heightened interest and growing demand for new treatments for Dry Eye Disease (DED). News of this latest funding round comes as BRIM prepares to initiate the Phase 3 clinical trial for its lead asset BRM421 for DED in the US. More>>

Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

Brussels, 30 November 2022 – Myeloma Patients Europe (MPE) has launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE) More>>

DSV BECOMES FIRST ETIHAD CARGO PARTNER TO PURCHASE SAF TO OFFSET CARBON EMISSIONS

 Etihad Cargo's partner, DSV, has become the carrier's first transport and logistics partner to purchase sustainable aviation fuel (SAF) to offset the carbon emissions of its shipment. Etihad's first NetZero transatlantic flight from Washington Dulles to Abu Dhabi utilised SAF combined with SAF Book & Claim, demonstrating the potential to utilise current technology to achieve net-zero aviation. The NetZero flight, operated with Etihad's Boeing 787 "Greenliner" programme, incorporated SATAVIA technology to prevent warming aircraft contrails. More>>

Recipharm Invests in its Single Dose Nasal Platform Capabilities

 Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose® Xtra (single dose) nasal delivery platform. More>>

Tower’s Latest Container Available For Free Demonstrations

21 November 2022 – Tower Cold Chain’s latest product for smaller pharmaceutical shipments, the KTEvolution container offering protection, security, and visibility in a small box, is now available for demonstration globally, at the company’s Centres of Excellence in the EMEA, APAC and Americas regions. More>>

Envirotainer Significantly Expands Global CryoSure® Network With New Singapore Station

Revolutionary -70°C cryogenic shipping now available across Asia and the Pacific

Stockholm, November 24, 2022: Envirotainer, the global market leader in secure cold chain solutions for shipment of pharmaceuticals, has opened a new CryoSure® station in Singapore. This significantly expands global availability of the ultra-cold solution for the transportation of medicines at -70°C. More>>

Etihad Cargo Achieves IATA CEIV Pharma Recertification for Pharmaceutical Logistics

Abu Dhabi, United Arab Emirates – Etihad Cargo, the cargo and logistics arm of Etihad Aviation Group, has been awarded Center of Excellence for Independent Validators (CEIV) Pharma recertification by the International Air Transport Association (IATA). The carrier is one of only 37 airlines to hold IATA CEIV Pharma certification globally. More>>

Shionogi, Active Citizenship Network and Meps Advocate for Urgent Policy Implementation in Eu Member States at Eu Parliament Event to Address the Growing Threat of Antimicrobial Resistance

OSAKA, Japan and AMSTERDAM, NL, 28 November 2022 – Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), held an event at the EU Parliament last week in the run-up to World Antimicrobial Awareness Week, joining forces with MEPs, Active Citizenship Network and MEPs Interest Group on "European Patients' Rights & Cross-Border Healthcare" to discuss initiatives to tackle AMR. The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue. More>>